NeuroStar Advanced Therapy for Mental Health Recognized as Top Neuromodulation Solution Provider in 2021

Neuronetics, Inc

MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) has been named Top Neuromodulation Solution Provider in 2021 by MedTech Outlook magazine. NeuroStar is the leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder. With over 4.3 million treatments delivered and countless lives transformed, a recent publication shows that NeuroStar achieved a high response rate of 83% and remission rate of 62% (Sackeim, et al).

“We are grateful to be recognized as a leader in the neuromodulation space,” said Keith J. Sullivan, President and CEO of Neuronetics. “Our goal is to offer a non-drug treatment to the millions of patients suffering from major depressive disorder – giving them a potential solution for a condition that can be challenging to manage. We are devoted to advancing our technology and spreading awareness to help change people’s lives.”

READ:  Omega Flex, Inc. Announces Organizational Changes

Along with the recognition is an article on, featuring NeuroStar’s technology, an overview of the programs and resources the company provides to physician practices and the vision for the company over the next five years.

To access the full list of the Top 10 Neuromodulation Solution Companies of 2021, visit MedTech Outlook here. For more information on NeuroStar, please visit

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.